Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06908057 · ClinicalTrials.gov registry record

Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)

A clinical trial of Type 1 Diabetes and Celiac Disease, sponsored by AdventHealth Translational Research Institute.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT06908057: Recruiting study of Type 1 Diabetes and Celiac Disease, sponsored by AdventHealth Translational Research Institute.

NCT06908057 is a study of Type 1 Diabetes and Celiac Disease that is actively recruiting participants, run by AdventHealth Translational Research Institute. The registered enrollment target is 200 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06908057, a study of Type 1 Diabetes and Celiac Disease, is actively recruiting participants, sponsored by AdventHealth Translational Research Institute.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to identify people with T1D or celiac disease (CD) early in the course of their disease and to improve the methods of screening for these diseases.

Primary Outcome

A blood sample will be drawn for islet-related autoantibodies. The initial autoantibody measurement will be done with the ECL research method which detects multiple autoantibodies at once. Positive results will be confirmed with a RBA validated for clinical use.

Interventions

  • OTHER Blood Draw

Study Locations (1)

Florida

  • AdventHealth Translational Research Institute - Orlando

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-03-11
Est. Completion 2026-06

What NCT06908057 shows while recruiting

NCT06908057 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (74% lower).

The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.

NCT06908057 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06908057 about?

NCT06908057 is a clinical study titled "Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)". The purpose of this study is to identify people with T1D or celiac disease (CD) early in the course of their disease and to improve the methods of screening for these diseases.

What is the current status of trial NCT06908057?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-03-11. Estimated completion is 2026-06.

What conditions does trial NCT06908057 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Celiac Disease.

What interventions are being tested in trial NCT06908057?

The interventions under investigation include: Blood Draw (OTHER).

Who is sponsoring clinical trial NCT06908057?

This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06908057 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06908057's enrollment target sits among peer trials

200 29th of 198 higher than 169 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06908057, the US trial registry maintained by the National Library of Medicine. NCT06908057 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.